GURNET POINT CAPITAL
Gurnet Point Capital is a leading healthcare fund that invests in de-risked life sciences companies. Gurnet Point primarily focuses on businesses that have high growth potential in the late product development and commercialization stages of their evolution. These companies become partners not just because of their capacity to generate economic value, but also because of their potential to deliver social impact. Gurnet Pointโs team of highly experienced industry executives work closely with its portfolio companies, with an active approach driving operational transformation and outsized returns. www.gurnetpointcapital.com
GURNET POINT CAPITAL
Social Links:
Industry:
Biotechnology Health Care Medical Device Pharmaceutical
Founded:
2015-01-01
Status:
Active
Contact:
617-588-4900
Email Addresses:
[email protected]
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Analytics LetsEncrypt Content Delivery Network Google Universal Analytics Font Awesome Apache
Similar Organizations
EpiVax
EpiVax is an immunology company developing comprehensive analytical capabilities in the field of computational immunology.
Current Advisors List
Current Employees Featured
Founder
Acquisitions List
Date | Company | Article | Price |
---|---|---|---|
2022-06-23 | Radius Health | Radius Health acquired by Gurnet Point Capital | 890 M USD |
2018-10-11 | Corium International | Corium International acquired by Gurnet Point Capital | 504 M USD |
2017-04-04 | Innocoll Holdings | Innocoll Holdings acquired by Gurnet Point Capital | 209 M USD |
Investments List
Date | Company | Article | Money raised |
---|---|---|---|
2022-06-22 | Alladapt Immunotherapeutics | Gurnet Point Capital investment in Venture Round - Alladapt Immunotherapeutics | 119 M USD |
2020-12-15 | Naveris | Gurnet Point Capital investment in Series A - Naveris | N/A |
2020-12-09 | Tremeau Pharmaceuticals | Gurnet Point Capital investment in Private Equity Round - Tremeau Pharmaceuticals | N/A |
2020-02-20 | Alladapt Immunotherapeutics | Gurnet Point Capital investment in Series C - Alladapt Immunotherapeutics | 60 M USD |
2017-03-20 | BEFORE Brands | Gurnet Point Capital investment in Series B - BEFORE Brands | 35 M USD |
2016-12-07 | Crossover Health | Gurnet Point Capital investment in Venture Round - Crossover Health | 92 M USD |
2016-12-01 | Auregen BioTherapeutics | Gurnet Point Capital investment in Venture Round - Auregen BioTherapeutics | N/A |
2016-10-05 | BEFORE Brands | Gurnet Point Capital investment in Series A - BEFORE Brands | 13.1 M USD |